. 2016 Mar 15;9:71–82. doi: 10.2147/DMSO.S65588

Table 1.

Efficacy results of randomized clinical trials with dapagliflozin add-on to metformin

	Duration, wk	Mean change in A_1C, %			Mean change in body weight, kg			Percentage of patients with A_1C <7%
		PBO	DAPA, mg/d		PBO	DAPA, mg/d		PBO	DAPA, mg/d
		PBO	5	10	PBO	5	10	PBO	5	10
Add-on to MET⁴¹,⁶⁰	24	−0.30	−0.70	−0.84	−0.90	−3.00	−2.90	25.9	37.5	40.6
Add-on to MET⁴¹,⁶⁰	102	0.02	−0.58	−0.78	1.36	−1.70	−1.74	15.4	26.4	31.5
Add-on to MET	24	−0.10	–	−0.39	−0.88	–	−2.96	–	–	–
DXA study³⁷,⁴²	102	0.12	–	−0.30	−2.12	–	−4.54	–	–	–
Add-on to	24	−0.39	−0.89	−0.96	0.43	−1.00	−1.61	–	–	–
INS ± MET⁴³,⁶¹	48	−0.47	−0.96	−1.01	0.82	−1.00	−1.61	–	–	–
INS ± MET⁴³,⁶¹	104^a	−0.43	−0.82	−0.78	1.83	−1.03	−1.50	–	–	–
Initial combination with MET⁶⁵	24	−1.35	−2.05	–	−1.29	−2.66	–	34.6	52.4	–
Initial combination with MET⁶⁵	24	−1.44	–	−1.98	−1.36	–	−3.33	35.2	–	46.6

		GLIP			GLIP

Add-on to MET vs GLIP add-on to MET⁴⁰,⁶³,⁶⁴	52	−0.52	–	−0.52	1.44	–	−3.22	–	–	–
	104	−0.14	–	−0.32	1.4	–	−3.7	–	–	–
	208	−0.10	–	−0.30	0.73	–	−4.38	–	–	–

		DAPA, 10 mg/d	SAXA, 5 mg/d	DAPA + SAXA	DAPA, 10 mg/d	SAXA, 5 mg/d	DAPA + SAXA	DAPA, 10 mg/d	SAXA, 5 mg/d	DAPA + SAXA

DAPA + SAXA add-on to MET⁶⁶	24	−1.20	−0.88	−1.47	−2.4	0	−2.1	22	18	41

Notes: Data are mean changes from baseline.

Patients receiving dapagliflozin 5 mg/d were uptitrated to 10 mg/d after 48 weeks of treatment and received this dose for the remainder of the 104-week trial.

Abbreviations: A_1C, glycated hemoglobin; DAPA, dapagliflozin; DXA, dual-energy X-ray absorptiometry; GLIP, glipizide; INS, insulin; MET, metformin; PBO, placebo; SAXA, saxagliptin.